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CG200745, an HDAC inhibitor, 
induces anti-tumour effects in 
cholangiocarcinoma cell lines 
via miRNAs targeting the Hippo 
pathway
Dawoon E. Jung1, Soo Been Park2, Kahee Kim3, Chanyang Kim3 & Si Young Song1,2,3
Cholangiocarcinoma is a devastating malignancy with fatal complications that exhibits low response 
and resistance to chemotherapy. Here, we evaluated the anticancer effects of CG200745, a novel 
histone deacetylase inhibitor, either alone or in combination with standard chemotherapy drugs in 
cholangiocarcinoma cells. CG200745 dose-dependently reduced the viability of cholangiocarcinoma 
cells in vitro and decreased tumour volume and weight in a xenograft model. Administering CG200745 
along with other chemotherapeutic agents including gemcitabine, 5-fluorouracil (5-FU), cisplatin, 
oxaliplatin, or gemcitabine plus cisplatin further decreased cholangiocarcinoma cell viability, with a 
combination index < 1 that indicated synergistic action. CG200745 also enhanced the sensitivity of 
gemcitabine-resistant cells to gemcitabine and 5-FU, thereby decreasing cell viability and inducing 
apoptosis. This was accompanied by downregulation of YAP, TEAD4, TGF-β2, SMAD3, NOTCH3, HES5, 
Axl, and Gas6 and upregulation of the miRNAs miR-22-3p, miR-22-5p, miR-194-5p, miR-194-3p, 
miR-194-5p, miR-210-3p, and miR-509-3p. The Ingenuity Pathway Analysis revealed that CG200745 
mainly targets the Hippo signalling pathway by inducing miR-509-3p expression. Thus, CG200745 
inhibits cholangiocarcinoma growth in vitro and in vivo, and acts synergistically when administered 
in combination with standard chemotherapeutic agents, enabling dose reduction. CG200745 is 
therefore expected to improve the outcome of cholangiocarcinoma patients who exhibit resistance to 
conventional therapies.
Cholangiocarcinoma is the second most common primary hepatobiliary cancer and has a poor prognosis, with 
5-year survival rates in the range of 5% to 15%1–3. More than two-thirds of cholangiocarcinoma patients have 
unresectable disease, and recurrence after curative resection is common. At present, gemcitabine-based regimens 
are considered as standard treatment for cholangiocarcinoma patients4, 5. Despite these advances in treatment, the 
number of cholangiocarcinoma-related deaths and chemotherapy-refractory cholangiocarcinoma cases continue 
to increase. Drug resistance in cholangiocarcinoma diminishes the therapeutic effects of gemcitabine-cisplatin; 
therefore, new agents that increase tumour sensitivity and can overcome drug resistance are urgently needed3, 6.
Histone acetylation/deacetylation is an epigenetic mechanism that modulates gene transcription via histone 
acetyltransferases and histone deacetylases (HDACs)7. Hyper- or hypoacetylation of oncogenes and tumour 
suppressor genes, respectively, is frequently observed in cancer cells8, 9. HDAC inhibitors are anti-cancer drugs 
that acetylate lysine residues in the N-terminal tails of histones, which inhibits their association with DNA and 
induces the expression of tumour suppressor genes. To date, two HDAC inhibitors—vorinostat and romidepsin—
have been approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma10. 
HDAC inhibitors have been shown to suppress cell proliferation in vitro and in vivo11–13, and can also rapidly alter 
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micro (mi)RNA levels to induce cell apoptosis in breast and pancreatic cancer and cholangiocarcinoma cells14–16. 
MiRNAs are small non-coding RNAs 21 to 23 nucleotides long that engage in post-transcriptional regulation of 
gene expression by silencing target mRNAs. MiRNA regulate various cellular processes including cell prolifera-
tion, differentiation, and apoptosis and their expression is often dysregulated in cancer17.
The HDAC inhibitor (E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy) methyl)
oct-2-enediamide (CG200745) was recently developed by CrystalGenomics. HDAC inhibitors are divided into 
four classes based on chemical structure—i.e., short-chain fatty acids, hydroxamic acids, depsipeptides, and ben-
zamides. CG200745 is an intravenous hydroxamate-based pan-HDAC inhibitor similar to vorinostat10 whose 
anti-proliferative effect has been demonstrated in several types of cancer cells, including prostate cancer, renal cell 
carcinoma, and colon cancer, either alone or in combination with other chemotherapy drugs. CG200745 was five 
times more effective than vorinostat in acetylating histone H3 in a colon cancer cell line, and induced acetylation 
of the tumour suppressor p53, leading to cancer cell death18. A previous study showed that treatment with HDAC 
inhibitor combined with other chemotherapy drugs resulted in an enhanced anti-proliferative effect and reduced 
toxicity in cholangiocarcinoma cells, and we recently demonstrated that CG200745 has anti-proliferative and 
synergistic effects in pancreatic cancer cells19, 20.
In this study, we investigated the anti-tumour effects of CG200745 in cholangiocarcinoma both in vitro and 
in vivo when administered alone or in combination with gemcitabine, 5-fluorouracil (5-FU), cisplatin, and oxalip-
latin. We assessed whether CG200745 can overcome the resistance of cholangiocarcinoma cells to gemcitabine 
and 5-FU, two standard chemotherapy drugs. We also analysed gene expression with cDNA and miRNA microar-
rays to clarify the molecular mechanisms underlying CG200745 action.
Results
CG200745 suppresses cholangiocarcinoma cell proliferation in vitro. The sensitivity of SNU-
1196, gemcitabine-resistant (GR) SNU-1196 (SNU-1196/GR), and SNU-308 cells to CG200745, entinostat, 
and vorinostat was determined based on half-maximal inhibitory concentration (IC50) values. To assess the 
effect of CG200745 on drug-sensitive and -resistant cells, we established the SNU-1196/GR cell line with a 
gemcitabine IC50 of 2.291 μM, which is approximately 60-fold higher than that in SNU-1196 (IC50 = 0.038 μM) 
(Supplementary Fig. 1a,b). These cells showed elevated expression of ATP-binding cassette (ABC) transporter 
ABCG2, as well as proto-oncogenes including c-MET and AKT, the epithelial-to-mesenchymal transition marker 
N-cadherin, and the tumour-initiating cell surface marker aldehyde dehydrogenase (ALDH) both in vitro and 
in vivo (Supplementary Figs 1c,d and 2). CG200745 treatment inhibited proliferation of SNU-1196, SNU-1196/
GR, and SNU-308 cells, with IC50 values of 0.63, 0.93, and 1.80 μM, respectively (Fig. 1a). CG200745 showed a 
lower IC50 relative to other HDAC inhibitors: vorinostat suppressed proliferation of SNU-1196, SNU-1196/GR, 
and SNU-308 cells with IC50 values of 1.2, 2.6, and 3.9 μM, respectively, whereas entinostat had IC50 values of 16.4, 
48.8, and 6.7 μM, respectively (Fig. 1b,c). Histone H3 acetylation was increased and expression of the apoptotic 
proteins p21 and B cell lymphoma (Bcl)-associated X protein (BAX) was induced by CG200745 treatment (Fig. 1d 
and Supplementary Fig. 3c). Moreover, CG200745 inhibited the expression of multidrug resistance (MDR) genes 
including ABCG2 and multidrug resistance-associated protein (MRP)4; human equilibrative nucleoside trans-
porter (hENT)1; the ABC transporters MRP1 and MRP3; and HDAC class II isozymes including HDAC4 and 
HDAC7 in SNU-1196, SNU-1196/GR, and SNU-308 cells (Figs 1e,f and. 3d,e).
Gemcitabine, cisplatin, 5-FU, and oxaliplatin in combination with CG200745 suppress prolifer-
ation of cholangiocarcinoma cells. We investigated the combined effects of standard chemotherapy drugs 
and CG200745 on SNU-1196 and SNU-308 cell proliferation. Each of the drugs tested—including gemcitabine, 
cisplatin, 5-FU, and oxaliplatin in combination with CG200745 (0.25 or 0.5 μM for SNU-1196 and 0.5 or 1.0 μM 
for SNU-308)—showed concentration-dependent cytotoxicity in both cell lines (Fig. 2a–d and Supplementary 
Fig. 4a–d). Upon treatment with 0.25 and 0.5 μM CG200745, the IC50 values of gemcitabine (0.038 μM) against 
SNU-1196 cells decreased to 0.002 and < 0.0001 μM, respectively; those of cisplatin (4.898 μM) decreased to 
0.562 and 0.105 μM, respectively; and those of 5-FU (104.713 μM) decreased to 1.862 and 0.01 μM, respectively. 
Similarly, the IC50 values of oxaliplatin (3.236 μM) decreased to 1.585 and 0.25 μM in the presence of 0.25 and 
0.5 μM CG200745, respectively (Supplementary Table 1a). In SNU-308 cells, upon treatment with 0.5 and 1.0 μM 
CG200745, the IC50 values of gemcitabine (1.413 μM) decreased to 0.32 and 0.13 μM, respectively; those of cispla-
tin (3.80 μM) decreased to 2.34 and 1.82 μM, respectively; and those of 5-FU (74.131 μM) decreased to 44.67 and 
17.78 μM, respectively. Similarly, the IC50 values of oxaliplatin (6.918 μM) decreased to 4.57 and 2.82 μM in the 
presence of 0.5 and 1.0 μM CG200745, respectively (Supplementary Table 2a).
We used CompuSyn software to calculate combination index (CI) and dose reduction index (DRI) to ana-
lyse the additive and synergistic effects of the standard chemotherapy drugs in combination with CG200745 
at different concentrations. CI < 1, CI = 1, and CI > 1 were indicative of synergistic, additive, and antagonistic 
effects, respectively. DRI measured the fold reduction in drug dose in a synergistic combination as compared to 
that of each drug alone, with DRI = 1, DRI > 1, and DRI < 1 indicating no dose reduction and favourable and 
unfavourable reductions, respectively. In SNU-1196 and SNU-308, CG200745 had both additive and synergistic 
effects in combination with gemcitabine, cisplatin, 5-FU, and oxaliplatin, as evidenced by the CI and DRI values 
(Supplementary Tables 1a,b and 2a,b). In SNU-1196, for instance, CG200745 exhibited synergistic cytotoxicity 
at different gemcitabine concentrations (0.001 to 10.0 μM), with CI values of 0.27 to 0.59 in the presence of 0.25 
or 0.5 μM CG200745, respectively (Supplementary Table 1b). Moreover, 0.038 μM of gemcitabine was required 
to achieve 50% inhibition; however, a 19-fold or lower concentration was required to achieve the same IC50 with 
0.25 μM CG200745 and 100-fold or lower concentration was required with 0.5 μM CG200745 (Supplementary 
Table 1a, Dose reduction index). Other drugs also showed synergism and favourable dose reduction with 
CG200745 (Supplementary Tables 1a,b and 2a,b). Likewise, synergistic concentration-dependent cytotoxicity was 
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observed in triple combinations of gemcitabine plus cisplatin in combination with CG200745 in both cell lines 
(0.5 μM for SNU-1196 and 1.0 μM for SNU-308) (Fig. 3a, Supplementary Fig. 4e, and Supplementary Tables 1c 
and 2c). CG200745 was found to reduce the expression of c-MET and increase that of cleaved Caspase-3, which 
was associated with increased apoptosis (Fig. 3b, and Supplementary Fig. 4f).
Gemcitabine or 5-FU combined with CG200745 suppresses proliferation of GR cholangiocarci-
noma cells. We established the SNU-1196/GR cell line to mimic the case where first-line chemotherapy fails 
due to the development of drug tolerance. Cells were treated with gemcitabine with or without CG200745. The 
IC50 of gemcitabine decreased from 2.291 to 0.209 and 0.048 μM in the presence of 0.25 and 0.5 μM CG200745, 
respectively (Fig. 4a). The IC50 of 5-FU (229.0 μM) decreased to 35.481, 6.761, and 0.417 μM upon treatment with 
0.25, 0.5, and 1.0 μM CG20074, respectively (Fig. 4b). These results suggest a synergistic cytotoxicity (CI < 1) 
Figure 1. Anti-proliferative activities of HDAC inhibitors against SNU-1196, SNU-1196/GR, and SNU-308 
cells. Cell viability was assessed with the MTT assay. (a) IC50 values of CG200745 were 0.6, 0.9, and 1.8 μM, 
respectively; (b) IC50 values of entinostat were 16.4, 48.8, and 6.7 μM, respectively; and (c) IC50 values of 
vorinostat were 1.2, 2.6, and 3.9 μM, respectively. In SNU-1196 and SNU-1196/GR cells, (d) CG200745 
(IC50) induced the expression of apoptosis-related proteins p21 and BAX, as determined by western blotting; 
(e) CG200745 (IC50) inhibited the expression of multidrug resistance genes, as determined by PCR; and (f) 
CG200745 (IC50) altered the expression level of HDAC isozyme, as determined by western blotting.
www.nature.com/scientificreports/
4SCIentIfIC RepoRts | 7: 10921  | DOI:10.1038/s41598-017-11094-3
(Supplementary Table 3b). Addition of CG200745 also increased the levels of cleaved Caspase-3 and poly (ADP 
ribose) polymerase (PARP), which was associated with increased apoptosis (Fig. 4c,d). Thus, CG200745 increased 
the sensitivity of cells to gemcitabine plus 5-FU in a dose-dependent manner.
CG200745 suppresses proliferation of cholangiocarcinoma cells in a xenograft model. In mice 
with SNU-1196 and SNU-1196/GR cell-derived tumours, CG200745 treatment decreased tumour volume and 
body weight relative to saline-treated mice. Average tumour volumes were 340.6 ± 57.1 and 599.4 ± 205.1 mm3 
for the SNU-1196 group and 398.8 ± 67.42 and 959.0 ± 73.80 mm3 for the SNU-1196/GR group injected with 
CG200745 and saline, respectively (Fig. 5a,b). Average tumour weights were 0.200 ± 0.024 and 0.469 ± 0.162 g for 
the SNU-1196 group and 0.217 ± 0.026 and 0.543 ± 0.055 g for the SNU-1196/GR group injected with CG200745 
and saline, respectively (Fig. 5c). Average body weights were 19.9 ± 0.55 and 21.9 ± 0.90 g for the SNU-1196 
group and 20.737 ± 0.545 and 22.717 ± 0.342 g for the SNU-1196/GR group injected with CG200745 and saline, 
respectively (Fig. 5d). All mice treated with CG200745 showed a < 10% decrease in body weight as compared to 
saline-treated animals. However, there were no significant differences tumour volume (P = 0.06) or body weight 
(P = 0.07) between the SNU-1196 groups.
Figure 2. Anti-proliferative effects of gemcitabine, cisplatin, 5-FU, and oxaliplatin in combination with 
CG200745. SNU-1196 cells were treated with (a) gemcitabine, (b) cisplatin, (c) 5-FU, and (d) oxaliplatin along 
with CG200745 and cell viability was evaluated with the MTT assay. *P ≤ 0.05, **P < 0.01, and ***P < 0.001.
Figure 3. Anti-proliferative effects of gemcitabine plus cisplatin in combination with CG200745. (a) SNU-
1196 cells were treated with indicated concentrations of gemcitabine plus cisplatin along with CG200745 and 
cell viability was assessed. G, gemcitabine; P, cisplatin; GP, gemcitabine plus cisplatin; CG, CG200745. (b) Cells 
treated with serial dose of gemcitabine plus cisplatin and CG200745 for 3 days showed downregulation of 
c-MET and upregulation of cleaved Caspase-3. GP50, gemcitabine IC50 plus cisplatin IC50; GP1, 1/64 dilution of 
GP50; GP2, 1/32 dilution of GP50; GP3, 1/16 dilution of GP50; GP4, 1/8 dilution of GP50.
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CG200745 alters gene and miRNA expression profiles in cholangiocarcinoma cells. The effects of 
CG200745 on SNU-1196 and SNU-1196/GR cells were assessed by cDNA and miRNA microarray analyses after 
24 h of treatment. Complete microarray data on differentially expressed genes (fold change ≥ 2 and P < 0.001) and 
miRNAs (fold change ≥ 1.5 and P < 0.01) are available in the Array Express database (E-MTAB-5733). The rela-
tionships between gene and miRNA expression patterns among CG200745-treated and untreated SNU-1196 and 
SNU-1196/GR cells were estimated by hierarchical clustering (Supplementary Fig. 5a,b). The overall expression 
patterns of genes and miRNAs were similar in both cell lines upon treatment with CG200745. A total of 465 dif-
ferentially expressed genes with a fold change ≥ 4.0 and P value of 0.1 × 10−10 were mapped by Ingenuity Pathway 
Analysis (IPA). There were 215 genes common to both cell lines; canonical pathways were analysed based on 
the ratio of the number of genes from the dataset that mapped to the pathway and a Fisher’s exact test value. 
The top statistically significant pathway was Hippo signalling; genes in this pathway including yes-associated 
protein (YAP), tafazzin (TAZ), and cluster of differentiation 44 were downregulated upon CG200745 treatment 
(Fig. 6a–c). Genes that were differentially expressed such as the Hippo pathway-associated transcription fac-
tor TEA domain transcription factor (TEAD)4; transforming growth factor (TGF)-β signalling-associated genes 
TGF-β2 and mothers against decapentaplegic homolog (SMAD)3; apoptosis-related genes AXL and growth 
arrest-specific (GAS)6; Notch signalling-associated genes NOTCH3 and Hairy and enhancer of split 5 (HES5); 
the pro-apoptotic gene p21; and proto-oncogenes including c-MET, AKT, mitogen-activated protein kinase, and 
extracellular signal-regulated kinase were also evaluated by IPA, and protein expression was confirmed by west-
ern blotting (Fig. 6d). Microarray and qRT-PCR analyses revealed that miR-22-3p, miR-22-5p, miR-194-5p, miR-
194-3p, miR-194-5p, and miR-210-3p were overexpressed in SNU-1196 and SNU-1196/GR cells treated with 
CG200745 (Fig. 7a,b). Interestingly, miR-509-3p was not expressed in untreated cells, but was induced by the 
presence of CG200745; the relative expression level was analysed after 12, 24, and 48 h of treatment instead of at 
0, 24, and 48 h. The expression of miR-22-3p, miR-192-5p, miR-194-5p, and miR-509-3p was evaluated by IPA 
and that of the putative targets YAP, AXL, and c-MET was determined in cells transfected with miRNA mimics 
(Fig. 7c,d). After 24 h, the levels of all three proteins were reduced in cells transfected with miR-509-3p (Fig. 7c).
To determine whether the increase in miR-509-3p expression induced by CG200745 altered YAP protein level, 
SNU-1196 and SNU-1196/GR cells were transfected with miR-509-3p inhibitor and miRNA mimics followed 
by treatment with CG200745 (0.05 and 0.5 μM). Cells transfected with miR-509-3p inhibitor had higher YAP 
protein levels than those transfected with the control sequence (Fig. 7e). Moreover, Acetylated histone H3 and 
cleaved-Caspase 3 were upregulated whereas YAP, TEAD4, and TGF-β2 were downregulated in mice treated with 
CG200745 relative to controls irrespective of the injected cell line. MiR-509-3p expression was also induced by 
CG200745 treatment (Fig. 8).
Figure 4. Anti-proliferative effects of gemcitabine and 5-FU combined with CG200745 in SNU-1196/GR. 
(a) SNU-1196/GR cells were treated with gemcitabine with or without CG200745. The IC50 of gemcitabine 
decreased from 2.291 to 0.209 μM at 0.25 μM CG200745 and to 0.048 μM at 0.5 μM CG200745; the value also 
decreased in SNU-1196/GR cells treated with 5-FU with or without CG200745 from 229.0 to 35.481 μM at 
0.25 μM CG200745, to 6.761 μM at 0.5 μM CG200745, and to 0.417 μM at 1.0 μM CG200745. (c,d) Treatment of 
SNU-1196/GR cells with CG200745 increased cleaved-Caspase-3 and PARP levels and induced apoptosis
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Discussion
HDAC inhibitors are the most widely used anti-cancer drugs targeting epigenetic modifications9 to selec-
tively alter gene expression. These compounds suppress the expression of genes involved in tumour progres-
sion, invasion, and angiogenesis. Vorinostat and entinostat induce the cyclin-dependent kinase inhibitor p21 to 
alter expression of proapoptic proteins of the Bcl-2 family21, 22, and have therapeutic potential for many types of 
malignancies including colon cancer, glioma, lung cancer, breast cancer, and hepatocellular carcinoma as a single 
treatment or in combination with other drugs23–26. However, the mechanism underlying the anticancer effects of 
HDAC inhibitor-induced acetylation is not well understood. Here we demonstrate that a novel HDAC inhibitor, 
CG200745, selectively targets Hippo signalling in cholangiocarcinoma cells to suppress proliferation and induce 
Figure 5. Anti-proliferative activity of CG200745 in cholangiocarcinoma cells in a xenograft model. (a,b) 
Tumour size was measured twice weekly and at the end of the experiment, mice were sacrificed and tumours 
were dissected. Tumour volume was decreased in SNU-1196 and SNU-1196/GR cells treated with CG200745. 
Average tumour volumes in SNU-1196-injected mice were 599.4 ± 205.1 and 340.6 ± 57.1 mm3 (P = 0.06) for 
the saline and CG200745 groups, respectively; in SNU-1196/GR-injected mice, they were 959.0 ± 73.80 and 
398.8 ± 67.42 mm3 (P < 0.001) for the saline and CG200745 groups, respectively. Five mice each were used 
for the SNU-1196 saline and CG200745 groups and six and eight mice were used for the SNU-1196/GR saline 
and CG200745 groups, respectively. Error bars represent SEM. ***p < 0.001. (c) Average tumour weights in 
SNU-1196-injected mice were 0.469 ± 0.162 and 0.200 ± 0.024 g (P = 0.07) for the saline and CG200745 groups, 
respectively; in SNU-1196/GR-injected mice, they were 0.543 ± 0.055 and 0.217 ± 0.026 g (P < 0.001) for the 
saline and CG200745 groups, respectively. Error bars are ± SEM. ***p < 0.001. (d) Average body weights of 
SNU-1196-injected mice were 21.9 ± 0.90 and 19.9 ± 0.55 g for the saline and CG200745 groups, respectively; 
in SNU-1196/GR-injected mice, they were 22.717 ± 0.342 and 20.737 ± 0.545 g for the saline and CG200745 
groups, respectively.
www.nature.com/scientificreports/
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apoptosis, acting either alone or synergistically with conventional chemotherapy drugs. Moreover, CG200745 
enhanced the sensitivity of gemcitabine-resistant cholangiocarcinoma cells to these drugs.
We recently reported that CG200745 either alone or combined with gemcitabine/erlotinib had synergis-
tic anti-tumour effects in pancreatic cancer cells20. In cholangiocarcinoma cells, CG200745 dose-dependently 
inhibited the proliferation of SNU-1196, SNU-1196/GR, and SNU-308 cells, an effect that was more potent than 
those of vorinostat and entinostat, which show 2- to 50-fold higher IC50 values in vitro. In a xenograft model, 
tumour volume and weight were reduced in both SNU-1196 and SNU-1196/GR groups administered CG200745, 
with < 10% decreases in body weight. Some HDAC inhibitors are of limited therapeutic use due to toxic side 
Figure 6. Target gene identification by microarray analysis. (a) Gene expression profiles were analysed with 
Affymetrix Human Genechip 2.0, and 215 differentially expressed genes (cut-off: fold change ≥ 4, P < 1.0E−10) 
were further examined by IPA. The graph shows the top cellular functions at 24 h post-CG200745 (IC50) 
treatment. (b) Genes differentially expressed in response to CG200745 (IC50) treatment in SNU-1196 and SNU-
1196/GR are shown in the heat map. Up- and downregulated genes are shown in red and green, respectively. 
(c) Top-ranked Hippo signalling-associated genes were downregulated (green). (d) Associations among highly 
ranked pathway-associated genes and corresponding protein levels were analysed following treatment with 
CG200745 (IC50) for 0, 24, and 48 h.
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effects at high doses; a lower IC50 can reduce these side effects. In human trials, CG200745 showed no toxicity at 
the tested doses, although a number of patients experienced grade 3 and 4 hematologic toxicity with symptoms 
such as anaemia and neutropenia that lasted for 1 week, as well as grade 1 and 2 toxicity including mild fatigue 
and anorexia27.
Gemcitabine-based regimens are the first-line chemotherapy for cholangiocarcinoma. Previous studies have 
shown that combined use of conventional drugs with HDAC inhibitors more potently inhibited cholangiocarci-
noma cell proliferation11, 13, 19, 28. CG200745 showed synergistic anti-tumour effects with gemcitabine, 5-FU, cis-
platin, and oxaliplatin in these cells, while combined treatment of low-dose chemotherapy drugs and CG200745 
showed greater inhibition of cell proliferation than either agent alone. Gemcitabine combined with cisplatin is 
a standard treatment for patients with advanced biliary tract cancer29. We found that the triple combination of 
gemcitabine, cisplatin, and CG200745 (0.5 μM) had both additive and synergistic effects and that the presence 
of CG200745 decreased IC50 by approximately 4-fold relative to treatment with gemcitabine plus cisplatin only.
The above-described effects may be due to CG200745-induced gene expression. The IPA revealed changes 
in gene expression at the mRNA level following treatment, including downregulation of the Hippo signal-
ling pathway components YAP, TAZ, and TEAD; these have been implicated in cancer development and can-
cer cell proliferation, invasion, and metastasis, while YAP is frequently hyperactivated in human cancers30, 31. 
TGF-β pathway-associated genes including TGF-β and SMAD and Notch signalling-associated genes were also 
downregulated in SNU-1196 and SNU-1196/GR cells. A previous study demonstrated that expression of the 
Figure 7. MiRNAs differentially expressed in response to CG200745 treatment and gene pathway analysis. 
(a) MiRNA expression profiles were analysed with a human Affymetrix GeneChip miRNA 4.0 Array and the 
expression induced by CG200745 treatment is shown in the heat map (upregulated, red). (b) Expression of 
individual miRNAs, as evaluated by qRT-PCR. *P ≤ 0.05, **P < 0.01, and ***P < 0.001. (c) SNU-1196 and 
SNU-1196/GR cells were transfected with miRNA mimics or a mimic control sequence and protein expression 
post-treatment (24 h) was analysed by western blotting. (d) Associations among highly ranked pathway-
associated-genes (downregulated, green) and differentially expressed miRNAs (upregulated, red) were analysed 
following treatment with CG200745 (IC50). Solid and dotted lines indicate direct and indirect interactions, 
respectively. (e) SNU-1196 and SNU-1196/GR cells were transfected with miR-509-3p inhibitor or an inhibitor 
control sequence followed by CG200745 treatment and protein expression post-treatment (48 h) was analysed 
by western blotting.
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apoptosis-inducing genes AXL and GAS6 was decreased by CG200745 treatment32. Interestingly, we observed 
that CG200745 altered the expression levels of miR-22-3p, miR-22-5p, miR-194-5p, miR-194-3p, miR-194-5p, 
miR-210-3p, and miR-509-3p. MiR-509-3p has been reported to act as a tumour suppressor by inhibiting gastric 
cancer cell proliferation and migration, and its overexpression was shown to induce apoptosis and inhibit breast 
and lung cancer cell invasion33, 34. MiR-509-3p was found to suppress metastasis in breast cancer cells and increase 
the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis35. It was also recently reported 
that miR-509-3p directly targets YAP and miR-509-3p mimic decreased YAP expression, thereby suppressing 
migration of ovarian cancer cells36. We observed that transient transfection of miR-509-3p mimic decreased YAP 
expression while miR-509-3p inhibitor abrogated the decrease in YAP expression induced by CG200745.
Gemcitabine-based regimens are routinely used to treat cholangiocarcinoma; however, the development of 
drug resistance is a major problem. This can be due to enhanced expression of ABC transporters in cancer cells37, 
38. Increased expression of the human ABC family genes ABCB, ABCC (which includes MRPs), and ABCG confers 
drug resistance to cancer cells by enhancing drug efflux39, while upregulation of ABCB1, ABCC1, and ABCG2 is 
linked to drug resistance in human pancreatic cancer40. The sensitivity of human pancreatic cancer to gemcitabine 
was shown to be dependent on the level of hENT1 expression41. The SNU-1196/GR cell line showed an approx-
imately 60-fold increase in tolerance to gemcitabine (IC50 = 2.291 μM) without losing sensitivity to CG200745 
(IC50 = 0.93 μM), and upregulated ABCG2 and MRP4 protein expression in vitro and in vivo (Supplementary 
Figure 8. Detection of genes and proteins differentially expressed in response to CG200745 treatment, as 
detected by in situ hybridization and immunohistochemistry, respectively. Tumour tissue was labelled with 
antibodies against acetylated histone H3, YAP, TEAD4, TGF-β2, and cleaved Caspase 3 and hybridised with an 
RNA probe targeting miR-509-3p.
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Fig. 1c), which was abrogated by CG200745. The expression of HDAC4, HDAC7, hENT1, and ABC transporters 
MRP1 and MRP3 in SNU-1196, SNU-1196/GR, and SNU-308 cells was also reduced by CG200745 treatment. 
HDAC4 and HDAC7 have been implicated in tumour growth, metastasis, and chemosensitivity42–44. A decrease 
in HDAC4 expression may result from upregulation of miRNAs targeting HDAC proteins, given that miR-22-3p 
was shown to target HDAC4 and that miR-22-3p expression was increased by CG200745 treatment45, 46. SNU-
1196/GR cells not only exhibited tolerance to gemcitabine but also stem-cell-like features. ALDH is a marker 
of cancer stem cells (CSCs) and is highly expressed in cholangiocarcinoma cells47. The expression of YAP and 
TEAD—another stem cell feature—was increased in basal breast cancers and was associated with enhanced tum-
origenic potential30, 31. CSCs contribute to tumour initiation, metastasis, recurrence, and chemotherapy resist-
ance48. Resistance to gemcitabine can arise from elevated expression of multidrug-resistance genes or an increase 
in the number of ALDH-positive cells CSCs; combined use of CG200745 with gemcitabine or 5-FU in SNU-1196/
GR cells resulted in more potent inhibition of cell growth. It is worth noting that the IC50 of SNU-1196/GR to gem-
citabine decreased more than 10 fold with 0.25 μM CG200745 and 45 fold with 0.5 μM CG200745 as compared to 
gemcitabine alone; the CI and DRI clearly demonstrated both the additive and synergistic effects of gemcitabine 
and CG200745. Similar trends were observed for 5-FU. However, we only examined the effect of CG200745 on 
SNU-1196/GR cells; although we attempted to establish GR SNU-308 cells, treatment with increasing doses of 
gemcitabine increased sensitivity by only 2 fold (Supplementary Fig. 3a).
In conclusion, our study characterised the novel HDAC inhibitor CG200745, which demonstrated 
anti-tumour effects against cholangiocarcinoma cells in vitro and in vivo with additive and synergistic effects 
when used in combination with standard chemotherapy drugs. Given the treatment complications such as drug 
resistance and toxicity associated with conventional therapies, adding CG200745 to the chemotherapeutic regi-
men could be a safer treatment for cholangiocarcinoma.
Methods
Cell culture. SNU-1196 and SNU-308 human cholangiocarcinoma cell lines were purchased from the Korean 
Cell Line Bank (Seoul, Korea) and were maintained in RPMI 1640 (Gibco, Grand Island, NY, USA) containing 
10% foetal bovine serum (Hyclone, Logan, UT, USA) in a humidified incubator of 5% CO2 at 37 °C. GR cell lines 
were established by treating cells with increasing doses of gemcitabine49, and resistance was determined by cell 
viability analysis. ALDH level was determined by western blotting; and enzymatic activity was measured using 
the ALDEFLUOR kit (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer’s proto-
col. Cells treated with the specific ALDH inhibitor diethylminobenzaldehyde was used as a negative control, and 
ALDH activity was measured by flow cytometry on an LSR II system (BD Biosciences, San Jose, CA, USA).
Reagents. CG200745 was provided by CrystalGenomics (Seoul, Korea). A 50-mM stock solution was pre-
pared in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA) and stored at −20 °C until use. HDAC 
inhibitors and chemotherapy drugs including vorinostat, entinostat, 5-FU, cisplatin, and oxaliplatin were pur-
chased from Selleck Chemicals (Houston, TX, USA); gemcitabine was supplied by Eli Lilly Korea (Seoul, Korea).
Cell viability assay. Cells were seeded at 3–5 × 103/well in 96-well plates and treated with various com-
pounds at a range of concentrations for 72 h. Cell viability was evaluated with the 3-(4,5-dimethylthiazol-2yl)-2,
5-diphenyltetrazolium bromide (MTT) assay (AMRESCO, Solon, OH, USA). Half-maximal inhibitory concen-
tration (IC50) was analysed relative to the DMSO control. Values are shown as the means of triplicate wells from 
three independent experiments for each drug concentration.
PCR. Total RNA was extracted using an RNeasy Mini kit (Qiagen, Hilden, Germany) and cDNA was synthe-
sised using a SuperScript II kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s protocol. β-Actin 
was used as a reference gene; primers are listed in Supplementary Table 4.
Microarray analysis. Total RNA containing miRNAs was extracted using a mirVana miRNA Isolation kit 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. For the cDNA microar-
ray, cDNA was synthesised using GeneChip Whole Transcript (WT) Amplification kit (Affymetrix, Santa Clara, 
CA, USA) according to the manufacturer’s instructions; sense cDNA was fragmented and biotin-labelled with ter-
minal deoxynucleotidyl transferase using the GeneChip WT Terminal labelling kit (Affymetrix). Approximately 
5.5 μg of labelled target DNA was hybridised to the Affymetrix GeneChip Human Gene 2.0 ST Array at 45 °C for 
16 h; hybridised arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned on a GCS3000 
instrument (Affymetrix). Export, processing, and analysis of array data were carried out using Affymetrix 
GeneChip Command Console (AGCC), Affymetrix Expression Console, and R 3.0.2 (www.r-project.org) soft-
ware. For the miRNA microarray, 1 μg of total RNA was biotin-labelled with the FlashTag Biotin HSR RNA 
Labelling kit (Affymetrix) and labelled samples were hybridised to a human Affymetrix GeneChip miRNA 
4.0 Array (Homo sapiens) using the GeneChip Hybridization Oven according to the manufacturer’s protocols. 
Arrays were scanned using the GeneChip Scanner and array data export, processing, and analysis were carried 
out using AGCC. Both cDNA and miRNA analyses were performed twice with independent sample sets. Pathway 
enrichment analysis was performed with Ingenuity Pathway Analysis (IPA) software (Qiagen), and differentially 
expressed genes were visualised with the MeV microarray analysis platform (www.tm4.org/mev.html).
Western blotting. Cells were lysed in a buffer composed of 70 mM glycerophosphate (pH 7.2), 0.6 mM Na 
vanadate, 2 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 0.5% Triton X-100, 0.2 mM phenylmethylsulfonyl 
fluoride, and 1 × complete protease inhibitor (Roche Applied Science, Nutley, NJ, USA). Proteins (25 μg) were 
separated on sodium dodecyl sulphate-polyacrylamide gels and transferred to a polyvinylidene difluoride mem-
brane (Immobilon-P; Millipore, Bedford, MA, USA) that was blocked in 5% (w/v) non-fat dry milk (Bio-Rad 
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Laboratories, Hercules, CA, USA) and incubated overnight at 4 °C with antibodies diluted 1:1000. Horseradish 
peroxidase-conjugated secondary antibody was used for detection and immunoblots were developed with West 
Pico Chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA). Antibodies used for western 
blot analysis are listed in Supplementary Table 5.
MiRNA quantitative reverse transcription (qRT-)PCR. qRT-PCR was carried out with the TaqMan 
Advanced miRNA cDNA Synthesis kit (Applied Biosystems), TaqMan Advanced miRNA Assay (Applied 
Biosystems), and TaqMan Gene Expression Master Mix according to the manufacturers’ protocols on an ABI 
Prism 7300 Sequence Detection System (Applied Biosystems). Primers for mature miRNAs were purchased from 
Applied Biosystems. Standard curves were generated and relative amounts of target miRNAs were normalised 
to that of miR-331-3p. Relative quantification of miRNAs within samples were calculated using the comparative 
Ct method (ΔCtpost-treatment − ΔCtpre-treatment = ΔΔCt; relative quantity = 2−ΔΔCt) and converted to fold changes. 
qRT-PCR reactions were prepared in triplicate from three different total RNA samples.
Transient transfection. Cells were transfected with pre-made miRNA mimics, mimic control sequence, 
miRNA inhibitors or inhibitor control sequence (all from Bioneer, Daejun, Korea) at a final concentration of 
20 nM using RNAiMAX (Invitrogen) in Opti-MEM (Gibco).
In vivo effects of CG200745. The study protocol was approved by the ethics committee of the Department 
of Laboratory Animal Resources, Yonsei Biomedical Research Institute, Yonsei University College of Medicine 
(2015-0205). Experiments were carried out using 6-week-old male BALB/c nude mice (Japan SLC, Yokohama, 
Japan), and were approved by the Institutional Animal Care and Use Committee of Yonsei University College of 
Medicine based on the Animal Protection Act. SNU-1196 and SNU-1196/GR cells in exponential phase (5 × 106/
mouse) were subcutaneously injected into the right flank. Drug treatment was initiated 2 weeks after tumour 
implantation when tumours had reached a volume of approximately 200 mm3. CG200745 (45 mg/kg) or saline 
was delivered into the peritoneum for 3 weeks (on days 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19). Tumour formation 
was monitored three times a week by measuring the width and length, and tumour volume was calculated using 
the formula: volume (mm3) = (length × width2)/2. Animals were sacrificed 3 weeks after the first administration.
Immunohistochemistry and in situ hybridization. Mouse tumour specimens were embedded in paraf-
fin and stained with hematoxylin and eosin according to standard protocols. For immunohistochemistry, sections 
of paraffin-embedded tissue were deparaffinised in xylene and rehydrated in a graded ethanol series. Endogenous 
peroxidase activity was blocked by incubation in methanol containing 0.3% hydrogen peroxide at room tem-
perature for 20 min. Antigen retrieval was performed in citrate buffer (0.01 M, pH 6.0), followed by blocking in 
10% normal donkey serum for 1 h at room temperature. Slides were incubated in primary antibody diluted 1:200 
in antibody diluent (Gibco) at 4 °C; antibodies are listed in Supplementary Table 5. The reaction was carried 
out using an Envision kit (Dako, Carpinteria, CA, USA). Sections were counterstained with hematoxylin. In 
situ hybridization was performed using Exiqon 5′-digoxigenin (DIG)-labelled miRCURY Locked Nucleic Acid 
(LNA) Detection probes to detect U6, scrambled miRNA, and hsa-miR-509-3p LNA probes. Deparaffinised and 
rehydrated tissue sections were treated with Proteinase K (20 μg/ml) at 37 °C for 10 min followed by paraform-
aldehyde (4%) fixation for 5 min. DIG-labelled probes were denatured at 90 °C for 5 min. Tissue was hybridised 
with probes (10 pmol/μl) and incubated at 53 °C overnight, and washed under stringent conditions at 53 °C. 
Hybridised probes were then detected with an anti-DIG antibody and visualised by incubation with NBT/BCIP 
alkaline phosphatase substrate solution (Roche Diagnostics, Indianapolis, IN, USA). Sections were counter-
stained with Neutral Red and imaged under a BX51 microscope (Olympus, Tokyo, Japan).
Drug combination studies. The effect of CG200745 combined with gemcitabine, cisplatin, 5-FU, oxalip-
latin, and gemcitabine plus cisplatin on cancer cell viability was evaluated in SNU-1196, SNU-1196/GR, and 
SNU-308 cells using the fixed-ratio method. Cells were treated with CG200745, gemcitabine, cisplatin, 5-FU, and 
oxaliplatin individually or in combination. The combination treatment consisted of 10-fold serial dilutions of 
gemcitabine and 5-FU and 5-fold dilutions of cisplatin and oxaliplatin with 0.25 or 0.5 μM CG200745. For triple 
combination treatment, gemcitabine and cisplatin were combined at a concentration ratio of 1:1 (gemcitabine 
IC50:cisplatin IC50 and 2-fold serial dilutions were prepared with 0.25 or 0.5 μM CG200745. After treatment, cell 
viability was determined with the MTT assay and dose-effect data for individual drugs and their combinations 
were analysed for synergism using CompuSyn software (http://www.combosyn.com/). CI values were calculated 
to characterise the nature of the drug interaction as defined by Chou and Talalay: CI =  1, additivity; CI  < 1, 
synergism; CI > 1, antagonism50. The DRI is a measure of the extent to which the dose of a drug in a synergistic 
combination must be reduced relative to the dose of the same drug alone to achieve a given effect level. The DRI 
value for each drug was also calculated.
Statistics. Data were analysed using SPSS v.11.0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism v.5.0 
(GraphPad Inc., La Jolla, CA, USA) software. Values for cell viability are expressed as the mean ± standard devi-
ation and values for the xenograft model are expressed as the mean ± standard error of the mean. Differences 
between groups were analysed with the t test, and P ≤ 0.05 was considered significant. Asterisks (*, **, and ***) 
indicate significance at P ≤ 0.05, P < 0.01, and P < 0.001, respectively.
Data availability. Cell line expression data are available in the ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-5733.
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